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Background: The occurrence of a respiratory syncytial virus (RSV) outbreak in a Neonatal Intensive Care Unit (NICU)
is related to unfavorable outcomes, as this infection can lead to respiratory distress and death in premature in
infants. Report the successful control of an outbreak that occurred in April 2010 in a NICU.
Methods: After the index case, of 18 premature infants placed in the same room 10 infants were infected. Of those
10, 6 developed mild to moderate respiratory symptoms, 4 persisted asymptomatic and no death occurred. Contact
and respiratory precautions were rapidly initiated, the infants were cohorted in 3 different rooms and palivizumab
was administered to all contacts.
Results: The outbreak was controlled and no new cases were subsequently indentified.
Conclusion: Standard infection control measures plus palivizumab prophylaxis were efficient in rapid control of the
outbreak.
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Respiratory syncytial Virus (RSV) is a single stranded RNA
virus of the Paramyxoviridae family. A and B sub-types are
involved in the majority of outbreaks; the A subtype in
responsible for most of them [1].
RSV can cause respiratory symptoms in patients of all
ages, but most cases occur in children under one year [2].
Special populations as premature infants born before
35 weeks of gestational age (GA), patients with underlying
lung disease and patients with congenital heart disease
are at risk of more morbidity and mortality from RSV
infection [3].
Transmission is most commonly by direct contact, as
the virus can remain for hours in surfaces and the hands
of health care workers [4]. When the virus circulates in
the general population, health care workers and visitors
can bring RSV to neonatal units. Infected infants are* Correspondence: livioandrade@yahoo.com.br
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reproduction in any medium, provided the orimportant sources of infection of others and they can
remain excreting virus for longer periods [5].
RSV outbreaks in NICU are expensive besides the
increased morbidity and mortality [6]. Conventional
infection control methods as hand hygiene and patient
isolation in cohorts are recommended, but those proce-
dures should be supplemented by the use of palivizumab,
a monoclonal antibody directed to glycoprotein F, as an
effective adjuvant to standard infection control measures
[7-9]. The aim of this manuscript is to report that the
combination of infection control measures with passive
immunotherapy in a country were new antiviral agents is
not easily available, succeeded in the rapid control of an
outbreak in NICU.
Methods
Our NICU is located at a Private Maternity Hospital in
São Paulo city with 1.000 births per month, has two
NICU situated in different floors of the building and
does not receive patients from other institutions. Each
unit has an overall capacity of 25 beds distributed in a. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Silva et al. Antimicrobial Resistance and Infection Control 2012, 1:16 Page 2 of 4
http://www.aricjournal.com/content/1/1/16large hall with 21 beds and three in the isolation room.
In addition, our hospital has one semi intensive care unit
with 21 beds, distributed in 5 different rooms. The outbreak
started in the NICU situated on the second floor.
Due to the seasonal characteristic of RSV in São Paulo
(April to August), the palivizumab prophylaxis is
indicated (intramuscular 15 mg/kg/day, each 30 days) to
infants less than 32 weeks of GA, or congenital heart
disease or chronic lung disease. The palivizumab
antibody use depends on each patient health insurance
authorization policy.
Routinely, the infant that presents respiratory symptoms
suggesting viral infection is tested for RSV using an
immunoassay test (QuickVue RSV test – bio Mérieux).
Contact and droplet precautions with gowns, gloves and
masks are promptly initiated in all suspect cases. The
nasopharyngeal RSV test is repeated after 14 days of the
diagnosis and then weekly to check the precautions
measures necessity.
It is considered as RSV infection all neonates who
present clinical evidence of lower respiratory tract infec-
tion and RSV immunoassay test positive. Neonate
asymptomatic carriage was defined as a positive RSV im-
munoassay test and no clinical respiratory symptoms
suggesting viral infection.
Protection rate of palivizumab was calculated by the
number of contacts neonates free of RSV symptomatic
disease who received palivizumab prophylaxis.
The suspicion of the present RSV outbreak began on 02
May 2010 as the first contact neonate of the index case
presented clinical respiratory symptoms of viral disease.Results
The index case occurred in a 27-week GA, 965 g of
birth weight preterm infant presenting on April 19th
tachypnoea, increase of respiratory secretions and
respiratory failure requiring mechanical ventilation. The
patient was 79 days old with bronchopulmonary dysplasia.
The infant received palivizumab in the same day his rapid
test became positive for RSV that means April 19th. At
that moment, contact and droplet precaution were
initiated. Two weeks apart the onset of RSV infection, the
RSV test was still positive.
On 02 May/10 and 03 May/10 two patients in the
same NICU of the index case developed respiratory
symptoms and tested positive for RSV. Prevention
control measures were then implemented and all infants
in the same room were tested for RSV, even in the
absence of respiratory symptoms. The cases and con-
tacts babies were moved to a semi intensive unit to bet-
ter cohort them into separate rooms as described below
(Figure 1). Hand hygiene and environmental cleaning
measures were reinforced.All babies (18 infants) occupying the NICU by the
moment of the outbreak were placed in 3 cohorts. Eight
of them with negative RSV test were maintained for
7 days in a room under contact precaution considering
RSV incubation period. None of these patients devel-
oped symptoms during this period and specific precau-
tions were suspended. The remaining 10 infants were
positive to RSV and they were placed into two different
rooms according to the presence or absence of symp-
toms. Six presented symptoms and four were asymp-
tomatic. All positive tested patients were isolated in
incubators and the use of gloves and mask was oriented
to visitors and staff personal.
All RSV positive infants were premature, average GA
was 28-weeks (range: 25-34w), birth weight of 1181
grams (range: 560-2575 g) and 50 days old (range: 26–97)
at RSV infection diagnosis. Patient characteristics are
shown in Table 1.
Symptomatic infants presented mild to moderate
symptoms, with cough, fever and coryza. Two patients
(cases 1, 4) and the index case, however, required venti-
lation support due to RSV infection. Cases 3, 5 and 8
were already under mechanical ventilation and required
an increase on ventilatory parameters after the infection.
Cases 6, 7, 9 and 10 did not present symptoms. No
specific antiviral treatment for RSV infection was
given, except palivizumab. In Brazil we do not have
inhalatory ribavirin avaible. No death occurred due to
RSV infection.
All contacts and the index case received palivizumab.
Cases 1, 2, 3 and 9, received palivizumab previously to
the onset of outbreak according to institutional policy
although cases 1, 2 and 3, presented respiratory symp-
toms of RSV infection. Palivizumab was prescribed to all
other 14 patients occupying the same NICU within the
beginning of the outbreak. Palivizumab protection rate
for symptomatic infection was 67% (12/18 cases).
RSV positive cases were weekly tested after 14 days of
the first detection and, in most cases, still positive at sub-
sequent tests. The longest viral shedding time was 5 weeks.
Symptomatic patients were isolated until hospital dis-
charge and the asymptomatic ones were removed from
the semi intensive unite when the viral test becomes nega-
tive. There were no new cases detected and the outbreak
was successfully controlled in 5 days (onset 2 May/10 and
last case 6 May/10).
Discussion
Besides index case, ten RSV cases were diagnosed in our
NICU, most of them under 28 weeks GA. Premature
infants are highly susceptible to RSV infection due to the
immaturity of their immunological system and the low
levels of maternal antibodies [10]. The occurrence of



















Figure 1 Summary of cases and contacts.
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patients included in this study no deaths occurred and
only 30% of the infected patients needed ventilation
support attributed to the infection.
Viral infection diagnosis is usually based on symptoms,
but, in an NICU outbreak the investigation of all
contacts is fundamental because of the possibility of
asymptomatic infection. Therefore asymptomatic and










Index case 27 965 g 79 2 weeks P
1 27 830 g 65 Negative control* H
2 27 585 g 46 3 weeks R
3 26 560 g 80 5 weeks R
4 33 1720 g 97 Negative control* O
5 25 795 g 51 3 weeks R
6 34 2575 g 38 3 weeks R
7 25 715 g 26 2 weeks R
8 25 650 g 26 2 weeks R
9 27 1230 g 32 Negative control* R
10 32 2150 g 37 2 weeks R
GA=Gestational Age; PDA =patent ductus arteriosus; BD=Bronchopulmonary dysp
hypertension; ARF = acute renal failure; MV=Mechanical ventilation; n-CPAP: nasal c
*Negative Control – negative test on the 14th day after diagnostic.isolated to avoid viral dissemination. Contact precautions
are well established as a control measure to RSV
outbreaks and the use of masks might be added when
the risk of respiratory particles dispersion is expected
[13]. We incorporated the use mask by visitors and staff
in order to prevent contamination and avoid carriers into
the NICU. It is recommended that infected patients
should be kept in cohorts away from the other healthy
prematures. Our strategy to transfer patients to otherive test
nderlying condition Respiratory symptoms Symptoms
DA/BPD Yes - MV due to RSV infection Yes
ydrocelle/GI Malformation YES – MV due to RSV infection Yes
DS/PDA/inguinal hernia MV - Worsening of parameters Yes
DS/PDA/BPD MV – worsening of parameters Yes
nphalocele/PDA/PH/BPD n-CPAP due to RSV Yes
DS/PDA/ARF MV–worsening of parameter s Yes
DS Previous in MV No
DS/PDA Previous in MV No
DS/PDA/BPD MV – worsening of parameter s Yes
DS/PDA No – No 02 Support No
DS No – No 02 support No
lasia; RDS = Respiratory distress syndrome; GI =Gastrointestinal; PH= Pulmonary
ontinuous positive airway pressure.
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the admission of other patients.
Usually, RSV shedding time last for 2 weeks, however,
under specific conditions such as immunosuppressed
hosts and preterm infants this period might be much
longer [5]. In the present study RSV excretion was docu-
mented for five weeks, showing that viral testing, despite
the role of detecting new cases, is crucial to determinate
the duration of precautions. The “quick test” to diagnose
RSV was chosen due to the simplicity of the method,
low cost and fast results. Dizdar et al. demonstrated the
use of a quick test as an efficient method in order to
identify and control a RSV NICU outbreak [9].
Presently, palivizumab use is not formally indicated in
outbreaks control. However, it may attenuate the gravity
of clinical manifestations and help to control viral
dissemination, according to some authors [7,9,11,14].
Despite the use of palivizumab, ten patients included in this
study presented with infection, six of them symptomatic
and four asymptomatic. We believe that palivizumab did
not prevent infection, probably because the infants were
already in the incubation period of RSV. The presented
symptoms however were mild and no death occurred.
The control of RSV nosocomial outbreaks remain a
challenge to medical staff and infection control practi-
tioners mainly because many institutions do not have
adequate isolation facilities. Early detection of cases,
reinforcement of hand hygiene and contact precaution
remains the most important measures to control
outbreaks. Although no independent analyses of each
measure could be done, we believe that the use of
palivizumab, contact and droplet precautions and the
periodic viral testing to determinate the suspension of
precautions were crucial for the successful control of
the outbreak.Competing interests
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